185 related articles for article (PubMed ID: 21547408)
1. Prognostic value of oncoprotein expressions in thyroid papillary carcinoma.
Balta AZ; Filiz AI; Kurt Y; Sucullu I; Yucel E; Akin ML
Med Oncol; 2012 Jun; 29(2):734-41. PubMed ID: 21547408
[TBL] [Abstract][Full Text] [Related]
2. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of nuclear 8-hydroxyguanosine expression in Autoimmune Thyroid Diseases and Papillary Thyroid Carcinoma and its relationship with p53, Bcl-2 and Ki-67 cancer related proteins.
Mseddi M; Ben Mansour R; Gouiia N; Mnif F; Bousselaa R; Abid M; Boudaouara T; Attia H; Lassoued S
Adv Med Sci; 2017 Mar; 62(1):45-51. PubMed ID: 28187375
[TBL] [Abstract][Full Text] [Related]
4. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
Akslen LA; Varhaug JE
Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of RET/PTC expression in papillary thyroid carcinoma and its correlation with prognostic factors in a north Indian population.
Mishra A; Agrawal V; Krishnani N; Mishra SK
J Postgrad Med; 2009; 55(3):171-5. PubMed ID: 19884740
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
Melck A; Masoudi H; Griffith OL; Rajput A; Wilkins G; Bugis S; Jones SJ; Wiseman SM
Ann Surg Oncol; 2007 Dec; 14(12):3403-11. PubMed ID: 17882495
[TBL] [Abstract][Full Text] [Related]
7. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R
Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and diagnostic significance of p53 protein expression in papillary thyroid carcinoma.
Shin MK; Kim JW
Asian Pac J Cancer Prev; 2014; 15(5):2341-4. PubMed ID: 24716981
[TBL] [Abstract][Full Text] [Related]
9. P53 protein profile by IHC may be helpful to define patient prognosis.
Marcello MA; Morari EC; Ward LS
Med Oncol; 2012 Sep; 29(3):2309-10. PubMed ID: 22722924
[No Abstract] [Full Text] [Related]
10. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
[TBL] [Abstract][Full Text] [Related]
11. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis].
Lu HZ; Zhang N; Liu W; Zhu XY; Qi D; Wang Y; Liu XY; Li ZJ
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):463-468. PubMed ID: 32575941
[No Abstract] [Full Text] [Related]
12. The Wnt/β-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer.
Zhang J; Gill AJ; Issacs JD; Atmore B; Johns A; Delbridge LW; Lai R; McMullen TP
Hum Pathol; 2012 Jul; 43(7):1044-50. PubMed ID: 22204713
[TBL] [Abstract][Full Text] [Related]
13. Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma.
Erdem H; Gündogdu C; Sipal S
Exp Mol Pathol; 2011 Jun; 90(3):312-7. PubMed ID: 21335003
[TBL] [Abstract][Full Text] [Related]
14. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
15. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
16. Expression characteristics of proteins of IGF-1R, p-Akt, and survivin in papillary thyroid carcinoma patients with type 2 diabetes mellitus.
Yan Y; Hu F; Wu W; Ma R; Huang H
Medicine (Baltimore); 2017 Mar; 96(12):e6393. PubMed ID: 28328831
[TBL] [Abstract][Full Text] [Related]
17. Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis.
Karlidag T; Cobanoglu B; Keles E; Alpay HC; Ozercan I; Kaygusuz I; Yalcin S; Sakallioglu O
Am J Otolaryngol; 2007; 28(1):31-6. PubMed ID: 17162129
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications.
Pickett CA; Agoff SN; Widman TJ; Bronner MP
Thyroid; 2005 May; 15(5):461-73. PubMed ID: 15929668
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of Cyclin D1 and P21 in the differential diagnosis of papillary thyroid carcinoma.
Wang CC; Lu DD; Shen MH; Chen RL; Zhang ZH; Lv JH
Diagn Pathol; 2023 Nov; 18(1):123. PubMed ID: 37951919
[TBL] [Abstract][Full Text] [Related]
20. Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions.
Brzeziańska E; Cyniak-Magierska A; Sporny S; Pastuszak-Lewandoska D; Lewiński A
Neuro Endocrinol Lett; 2007 Aug; 28(4):341-50. PubMed ID: 17693985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
